Financings in Brief: Davinci Scientific Corporation
This article was originally published in The Gray Sheet
Executive Summary
Davinci Scientific Corporation: Files registration statement for an initial public offering of 1.3 mil. units, each consisting of one common share and one four-year warrant to buy one common share. The company, formed in 1992, aims to acquire "emerging medical technologies and technology companies" whose products are cleared by FDA and protected by patents, but "have not been effectively marketed to the healthcare community." Davinci has acquired rights to one product, the Resusci-Cath minimally invasive arterial oxygen monitor. The firm also has owns 44% of cardiac monitoring manufacturer CardioDynamics and 5% of Vital Heart Systems, a developer of a non-invasive variance cardiography diagnostic product.